LPCN vs PATH · rev $11.2M vs P/E 19, rev $1.61B
Lipocine Inc (LPCN) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Lipocine Inc (LPCN) is a biotechnology company listed on NASDAQ.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported LPCN revenue for 2024-12-31 was $11.2M. Net income was $8.4K. Revenue was up 492.8% from 2023-12-31 to 2024-12-31. LPCN currently screens at market cap $19.3M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
LPCN currently screens at market cap $19.3M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the LPCN and PATH stock pages for the full models.
Not investment advice.